Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

The Word Brain 2015Free PDF | Print | Web
A short guide to fast language learning

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 80 articles:
HTML format
Text format



Single Articles


    September 2016
  1. SARRABAYROUSE G, Pich C, Teiti I, Tilkin-Mariame AF, et al
    Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30422.
    PubMed     Text format     Abstract available


    August 2016
  2. ZHANG W, Liu H, Yin J, Wu W, et al
    Genetic Variants in the PIWI-piRNA Pathway Gene DCP1A Predict Melanoma Disease-specific Survival.
    Int J Cancer. 2016 Aug 31. doi: 10.1002/ijc.30409.
    PubMed     Text format     Abstract available


  3. ROCKBERG J, Amelio JM, Taylor A, Jorgensen L, et al
    Epidemiology of cutaneous melanoma in Sweden - stage specific survival and rate of recurrence.
    Int J Cancer. 2016 Aug 26. doi: 10.1002/ijc.30407.
    PubMed     Text format     Abstract available


    June 2016
  4. VAYSSE A, Fang S, Brossard M, Wei Q, et al
    A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants.
    Int J Cancer. 2016 Jun 27. doi: 10.1002/ijc.30245.
    PubMed     Text format     Abstract available


  5. MAXWELL R, Garzon-Muvdi T, Lipson EJ, Sharfman WH, et al
    BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.
    Int J Cancer. 2016 Jun 25. doi: 10.1002/ijc.30241.
    PubMed     Text format     Abstract available


  6. MIRZAEI H, Naseri G, Rezaee R, Mohammadi M, et al
    Curcumin: A new candidate for melanoma therapy?
    Int J Cancer. 2016 Jun 9. doi: 10.1002/ijc.30224.
    PubMed     Text format     Abstract available


  7. GANDINI S, Ferrucci PF, Botteri E, Tosti G, et al
    Prognostic significance of hematological profiles in melanoma patients.
    Int J Cancer. 2016 Jun 2. doi: 10.1002/ijc.30215.
    PubMed     Text format     Abstract available


    May 2016
  8. ORTEGA-MARTINEZ I, Gardeazabal J, Erramuzpe A, Sanchez-Diez A, et al
    Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early stage melanoma.
    Int J Cancer. 2016 May 23. doi: 10.1002/ijc.30202.
    PubMed     Text format     Abstract available


  9. POTRONY M, Carreras E, Aranda F, Zimmer L, et al
    Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.
    Int J Cancer. 2016 May 11. doi: 10.1002/ijc.30184.
    PubMed     Text format     Abstract available


    April 2016
  10. TAYLOR NJ, Thomas NE, Anton-Culver H, Armstrong BK, et al
    Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma.
    Int J Cancer. 2016 Apr 22. doi: 10.1002/ijc.30157.
    PubMed     Text format     Abstract available


  11. SMALLEY KS, Fedorenko IV, Kenchappa R, Sahebjam S, et al
    Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.
    Int J Cancer. 2016 Apr 15. doi: 10.1002/ijc.30147.
    PubMed     Text format     Abstract available


  12. ANDZINSKI L, Kasnitz N, Stahnke S, Wu CF, et al
    Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human.
    Int J Cancer. 2016;138:1982-93.
    PubMed     Text format     Abstract available


    March 2016
  13. SIMBERG-DANELL C, Lyth J, Mansson-Brahme E, Frohm-Nilsson M, et al
    Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.
    Int J Cancer. 2016 Mar 23. doi: 10.1002/ijc.30103.
    PubMed     Text format     Abstract available


  14. ROWE CJ, Tang F, Hughes MC, Rodero MP, et al
    Molecular markers to complement sentinel node status in predicting survival in patients with high risk locally invasive melanoma.
    Int J Cancer. 2016 Mar 14. doi: 10.1002/ijc.30085.
    PubMed     Text format     Abstract available


    February 2016
  15. NAGORE E, Heidenreich B, Rachakonda S, Garcia-Casado Z, et al
    TERT promoter mutations in melanoma survival.
    Int J Cancer. 2016 Feb 13. doi: 10.1002/ijc.30042.
    PubMed     Text format     Abstract available


  16. DEVARAPU SK, Mamidi S, Ploger F, Dill O, et al
    Cytotoxic Activity Against Human Neuroblastoma and Melanoma Cells Mediated by IgM Antibodies Derived from Peripheral Blood of Healthy Donors.
    Int J Cancer. 2016 Feb 2. doi: 10.1002/ijc.30025.
    PubMed     Text format     Abstract available


    January 2016
  17. ERIKSSON H, Lyth J, Andersson TM
    The proportion cured of patients diagnosed with stage III-IV cutaneous malignant melanoma in Sweden 1990-2007: A population-based study.
    Int J Cancer. 2016 Jan 27. doi: 10.1002/ijc.30023.
    PubMed     Text format     Abstract available


    December 2015
  18. OROUJI E, Orouji A, Gaiser T, Larribere L, et al
    MAP Kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Int J Cancer. 2015 Dec 18. doi: 10.1002/ijc.29970.
    PubMed     Text format     Abstract available


  19. THOMSEN FB, Folkvaljon Y, Garmo H, Robinson D, et al
    Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study.
    Int J Cancer. 2015 Dec 14. doi: 10.1002/ijc.29961.
    PubMed     Text format     Abstract available


    September 2015
  20. LERRO CC, Koutros S, Andreotti G, Hines CJ, et al
    Use of acetochlor and cancer incidence in the Agricultural Health Study.
    Int J Cancer. 2015;137:1167-75.
    PubMed     Text format     Abstract available


    August 2015
  21. WISTUBA-HAMPRECHT K, Di Benedetto S, Schilling B, Sucker A, et al
    Phenotypic characterization and prognostic impact of circulating gammadelta and alphabeta T-cells in metastatic malignant melanoma.
    Int J Cancer. 2015 Aug 27. doi: 10.1002/ijc.29818.
    PubMed     Text format     Abstract available


  22. CORREA D, Somoza RA, Lin P, Schiemann WP, et al
    Mesenchymal Stem Cells regulate Melanoma Cancer Cells extravasation to bone and liver at their perivascular niche.
    Int J Cancer. 2015 Aug 1. doi: 10.1002/ijc.29709.
    PubMed     Text format     Abstract available


  23. AL-AHMADY ZS, Scudamore CL, Kostarelos K
    Triggered doxorubicin release in solid tumors from thermosensitive liposome-peptide hybrids: Critical parameters and therapeutic efficacy.
    Int J Cancer. 2015;137:731-43.
    PubMed     Text format     Abstract available


    June 2015
  24. RIBERO S, Davies JR, Glass D, Quaglino P, et al
    RE:RE: High naevus counts confer a favorable prognosis in melanoma patients.
    Int J Cancer. 2015 Jun 24. doi: 10.1002/ijc.29652.
    PubMed     Text format    


  25. AUTIER P, Funck-Brentano E, Aegerter P, Boniol M, et al
    Re: High nevus counts confer a favorable prognosis in melanoma patients by S Ribero and co-workers, published in the International Journal of Cancer, 2015 (Online 21 March 2015).
    Int J Cancer. 2015 Jun 20. doi: 10.1002/ijc.29648.
    PubMed     Text format    


    May 2015
  26. WAGNER NB, Weide B, Reith M, Tarnanidis K, et al
    Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.
    Int J Cancer. 2015 May 27. doi: 10.1002/ijc.29619.
    PubMed     Text format     Abstract available


  27. WALLINGFORD SC, Iannacone MR, Youlden DR, Baade PD, et al
    Comparison of melanoma incidence and trends among youth under 25 years in Australia and England, 1990-2010.
    Int J Cancer. 2015 May 8. doi: 10.1002/ijc.29598.
    PubMed     Text format     Abstract available


  28. HELGADOTTIR H, Hoiom V, Tuominen R, Jonsson G, et al
    CDKN2A mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Int J Cancer. 2015 May 5. doi: 10.1002/ijc.29595.
    PubMed     Text format     Abstract available


    April 2015
  29. BROSSARD M, Fang S, Vaysse A, Wei Q, et al
    Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at TERF1 and AFAP1L2 loci on melanoma risk.
    Int J Cancer. 2015 Apr 17. doi: 10.1002/ijc.29570.
    PubMed     Text format     Abstract available


    March 2015
  30. BRAMANTE S, Kaufmann JK, Veckman V, Liikanen I, et al
    Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
    Int J Cancer. 2015 Mar 26. doi: 10.1002/ijc.29536.
    PubMed     Text format     Abstract available


  31. RIBERO S, Davies JR, Requena C, Carrera C, et al
    High naevus counts confer a favourable prognosis in melanoma patients.
    Int J Cancer. 2015 Mar 21. doi: 10.1002/ijc.29525.
    PubMed     Text format     Abstract available


  32. WANG J, Yu F, Jia X, Iwanowycz S, et al
    MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.
    Int J Cancer. 2015;136:E602-13.
    PubMed     Text format     Abstract available


  33. MAULDIN IS, Wang E, Deacon DH, Olson WC, et al
    TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.
    Int J Cancer. 2015 Mar 12. doi: 10.1002/ijc.29515.
    PubMed     Text format     Abstract available


  34. JOSHI S, Wels C, Beham-Schmid C, Fukunaga-Kalabis M, et al
    Galpha(13) mediates human cytomegalovirus-encoded chemokine receptor US28 induced cell death in melanoma.
    Int J Cancer. 2015 Mar 6. doi: 10.1002/ijc.29506.
    PubMed     Text format     Abstract available


  35. DOBERSTEIN K, Harter PN, Haberkorn U, Bretz NP, et al
    Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT.
    Int J Cancer. 2015;136:E326-39.
    PubMed     Text format     Abstract available


    February 2015
  36. LAUBER S, Wong S, Cutz JC, Tanaka M, et al
    Novel function of Oncostatin M as a potent tumour-promoting agent in lung.
    Int J Cancer. 2015;136:831-43.
    PubMed     Text format     Abstract available


  37. SIURALA M, Bramante S, Vassilev L, Hirvinen M, et al
    Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
    Int J Cancer. 2015;136:945-54.
    PubMed     Text format     Abstract available


  38. SADEGH L, Chen PW, Brown JR, Han Z, et al
    NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases.
    Int J Cancer. 2015 Feb 14. doi: 10.1002/ijc.29480.
    PubMed     Text format     Abstract available


    January 2015
  39. JUNG JW, Overgaard NH, Burke MT, Isbel N, et al
    Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?
    Int J Cancer. 2015 Jan 22. doi: 10.1002/ijc.29450.
    PubMed     Text format     Abstract available


  40. CHENG M, Ahmed M, Xu H, Cheung NK, et al
    Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
    Int J Cancer. 2015;136:476-86.
    PubMed     Text format     Abstract available


  41. YUAN H, Liu H, Liu Z, Zhu D, et al
    Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival.
    Int J Cancer. 2015 Jan 13. doi: 10.1002/ijc.29429.
    PubMed     Text format     Abstract available


  42. YUE C, Xu J, Tan Estioko MD, Kotredes KP, et al
    Host STAT2/type I interferon axis controls tumor growth.
    Int J Cancer. 2015;136:117-26.
    PubMed     Text format     Abstract available


  43. GEBREMESKEL S, LeVatte T, Liwski RS, Johnston B, et al
    The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer.
    Int J Cancer. 2015;136:234-40.
    PubMed     Text format     Abstract available


    December 2014
  44. JOUVE N, Bachelier R, Despoix N, Blin MG, et al
    CD146 mediates VEGF-induced melanoma cell extravasation through FAK activation.
    Int J Cancer. 2014 Dec 2. doi: 10.1002/ijc.29370.
    PubMed     Text format     Abstract available


    November 2014
  45. KVASKOFF M, Pandeya N, Green AC, Perry S, et al
    Solar elastosis and cutaneous melanoma: A site-specific analysis.
    Int J Cancer. 2014 Nov 18. doi: 10.1002/ijc.29335.
    PubMed     Text format     Abstract available


  46. NEWTON-BISHOP JA, Davies JR, Latheef F, Randerson-Moor J, et al
    25-hydroxyvitamin D /D levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort.
    Int J Cancer. 2014 Nov 18. doi: 10.1002/ijc.29334.
    PubMed     Text format     Abstract available


  47. TUOMINEN R, Jewell R, van den Oord JJ, Wolter P, et al
    MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
    Int J Cancer. 2014 Nov 15. doi: 10.1002/ijc.29332.
    PubMed     Text format     Abstract available


  48. TAYLOR NJ, Reiner AS, Begg CB, Cust AE, et al
    Inherited variation at MC1R and ASIP and association with melanoma-specific survival.
    Int J Cancer. 2014 Nov 10. doi: 10.1002/ijc.29317.
    PubMed     Text format     Abstract available


  49. LOUMAGNE L, Baudhuin J, Favier B, Montespan F, et al
    In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance.
    Int J Cancer. 2014;135:2107-17.
    PubMed     Text format     Abstract available


    October 2014
  50. JIANG H, Gebhardt C, Umansky L, Beckhove P, et al
    Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.
    Int J Cancer. 2014 Oct 29. doi: 10.1002/ijc.29297.
    PubMed     Text format     Abstract available


  51. OSELLA-ABATE S, Ribero S, Sanlorenzo M, Maule MM, et al
    Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years.
    Int J Cancer. 2014 Oct 21. doi: 10.1002/ijc.29281.
    PubMed     Text format     Abstract available


  52. LAW MH, Rowe C, Montgomery GW, Hayward NK, et al
    PARP1 polymorphisms play opposing roles in melanoma occurrence and survival.
    Int J Cancer. 2014 Oct 21. doi: 10.1002/ijc.29280.
    PubMed     Text format    


  53. IBARROLA-VILLAVA M, Kumar R, Nagore E, Benfodda M, et al
    Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition.
    Int J Cancer. 2014 Oct 10. doi: 10.1002/ijc.29257.
    PubMed     Text format     Abstract available


  54. RUFFINI F, Graziani G, Levati L, Tentori L, et al
    Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of alphavbeta5 integrin.
    Int J Cancer. 2014 Oct 4. doi: 10.1002/ijc.29252.
    PubMed     Text format     Abstract available


    September 2014
  55. KHALKHALI-ELLIS Z, Kirschmann DA, Seftor EA, Gilgur A, et al
    Divergence(s) in Nodal signaling between aggressive melanoma and embryonic stem cells.
    Int J Cancer. 2014 Sep 9. doi: 10.1002/ijc.29198.
    PubMed     Text format     Abstract available


  56. FANG S, Wang Y, Chun YS, Liu H, et al
    The relationship between blood IL-12p40 level and melanoma progression.
    Int J Cancer. 2014 Sep 5. doi: 10.1002/ijc.29182.
    PubMed     Text format     Abstract available


    August 2014
  57. VAN HAUWERMEIREN F, Vandenbroucke RE, Grine L, Puimege L, et al
    Antisense oligonucleotides against TNFR1 prevent toxicity of TNF/IFNgamma treatment in mouse tumor models.
    Int J Cancer. 2014;135:742-50.
    PubMed     Text format     Abstract available


  58. CHEN JL, Dawoodji A, Tarlton A, Gnjatic S, et al
    NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 Fowlpox virus.
    Int J Cancer. 2014 Aug 1. doi: 10.1002/ijc.29118.
    PubMed     Text format     Abstract available


    July 2014
  59. BARRETT JH, Taylor JC, Bright C, Harland M, et al
    Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions.
    Int J Cancer. 2014 Jul 31. doi: 10.1002/ijc.29099.
    PubMed     Text format     Abstract available


  60. IZRAELY S, Sagi-Assif O, Klein A, Meshel T, et al
    The Metastatic Microenvironment: Claudin-1 Suppresses the Malignant Phenotype of Melanoma Brain Metastasis.
    Int J Cancer. 2014 Jul 21. doi: 10.1002/ijc.29090.
    PubMed     Text format     Abstract available


    June 2014
  61. WOLNICKA-GLUBISZ A, Strickland FM, Wielgus A, Anver M, et al
    A melanin-independent interaction between Mc1r and Met signalling pathways is required for HGF-dependent melanoma.
    Int J Cancer. 2014 Jun 28. doi: 10.1002/ijc.29050.
    PubMed     Text format     Abstract available


  62. JAYAWARDANA K, Schramm SJ, Haydu L, Thompson JF, et al
    Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information.
    Int J Cancer. 2014 Jun 27. doi: 10.1002/ijc.29047.
    PubMed     Text format     Abstract available


  63. PASQUALI E, Garcia-Borron JC, Fargnoli MC, Gandini S, et al
    MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: A pooled-analysis from the M-SKIP project.
    Int J Cancer. 2014 Jun 10. doi: 10.1002/ijc.29018.
    PubMed     Text format     Abstract available


  64. ZHONG H, Gutkin DW, Han B, Ma Y, et al
    Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.
    Int J Cancer. 2014;134:2633-45.
    PubMed     Text format     Abstract available


    May 2014
  65. JUNG JI, Cho HJ, Jung YJ, Kwon SH, et al
    High-fat diet-induced obesity increases lymphangiogenesis and lymph node metastasis in the B16F10 melanoma allograft model: Roles of adipocytes and M2-macrophages.
    Int J Cancer. 2014 May 20. doi: 10.1002/ijc.28983.
    PubMed     Text format     Abstract available


  66. ZORNIG I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, et al
    Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
    Int J Cancer. 2014 May 17. doi: 10.1002/ijc.28980.
    PubMed     Text format     Abstract available


  67. IANNACONE MR, Youlden DR, Baade PD, Aitken JF, et al
    Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia.
    Int J Cancer. 2014 May 8. doi: 10.1002/ijc.28956.
    PubMed     Text format     Abstract available


    April 2014
  68. HOSOI A, Matsushita H, Shimizu K, Fujii S, et al
    Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
    Int J Cancer. 2014;134:1810-22.
    PubMed     Text format     Abstract available


  69. DIHLMANN S, Tao S, Echterdiek F, Herpel E, et al
    Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients.
    Int J Cancer. 2014 Apr 12. doi: 10.1002/ijc.28891.
    PubMed     Text format     Abstract available


    March 2014
  70. XIE L, Yui J, Fujinaga M, Hatori A, et al
    Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe F-FITM.
    Int J Cancer. 2014 Mar 18. doi: 10.1002/ijc.28842.
    PubMed     Text format     Abstract available


  71. JABLONSKA J, Wu CF, Andzinski L, Leschner S, et al
    CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-beta.
    Int J Cancer. 2014;134:1346-58.
    PubMed     Text format     Abstract available


  72. BRAUN J, Strittmatter K, Nubel T, Komljenovic D, et al
    Loss of stromal JUNB does not affect tumor growth and angiogenesis.
    Int J Cancer. 2014;134:1511-6.
    PubMed     Text format     Abstract available


  73. BEETON-KEMPEN N, Duarte J, Shoko A, Serufuri JM, et al
    Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens.
    Int J Cancer. 2014 Mar 6. doi: 10.1002/ijc.28832.
    PubMed     Text format     Abstract available


    February 2014
  74. DAVIES JR, Jewell R, Affleck P, Anic GM, et al
    Inherited variation in the PARP1 gene and survival from melanoma.
    Int J Cancer. 2014 Feb 18. doi: 10.1002/ijc.28796.
    PubMed     Text format     Abstract available


  75. WANG Q, Beaumont KA, Otte NJ, Font J, et al
    Targeting glutamine transport to suppress melanoma cell growth.
    Int J Cancer. 2014 Feb 17. doi: 10.1002/ijc.28749.
    PubMed     Text format     Abstract available


  76. MAMLOUK S, Kalucka J, Singh RP, Franke K, et al
    Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development.
    Int J Cancer. 2014;134:849-58.
    PubMed     Text format     Abstract available


    January 2014
  77. LABAN S, Atanackovic D, Luetkens T, Knecht R, et al
    Simultaneous cytoplasmic and nuclear protein expression of MAGE-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head & neck cancer.
    Int J Cancer. 2014 Jan 31. doi: 10.1002/ijc.28752.
    PubMed     Text format     Abstract available


  78. IWAMOTO H, Ojima T, Hayata K, Katsuda M, et al
    Antitumor immune response of dendritic cells (DCs) expressing tumor-associated antigens derived from induced pluripotent stem cells: in comparison to bone marrow-derived DCs.
    Int J Cancer. 2014;134:332-41.
    PubMed     Text format     Abstract available


    November 2013
  79. FU X, Rivera A, Tao L, Zhang X, et al
    Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery.
    Int J Cancer. 2013;133:2483-92.
    PubMed     Text format     Abstract available


    May 2013
  80. VOGETSEDER A , Thies S, Ingold B, Roth P, et al
    alphav-Integrin isoform expression in primary human tumors and brain metastases.
    Int J Cancer. 2013 May 10. doi: 10.1002/ijc.28267.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Pfizer Oncology.

Design: